Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium infantis cure 21 + lactobacillus plantarum 299
- Development stage
- Discontinued
- Lead developer
- Probi
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A combination probiotic product containing two specific live bacterial strains: Lactobacillus plantarum 299 (also known as Lp299v) and Bifidobacterium infantis Cure 21. It is classified as a biologic therapy and was investigated in a randomized, double-blind, placebo-controlled trial for patients with poor ileal pouch function following proctocolectomy for ulcerative colitis. The proposed mechanism involves modulating the gut microbiome to reduce inflammation and improve intestinal function. However, the pivotal study did not demonstrate a significant benefit over placebo in improving pouch functional scores or inflammation markers, and the hypothesis that it improves pouch-related dysfunction was not confirmed. The Lactobacillus plantarum 299v strain is developed by Probi AB.
- Other names
- Lactobacillus plantarum 299 and Bifidobacterium infantis Cure 21
02
Targets
AJC (Intestinal epithelial junctional complex)
Beyond the preview
Go deeper on bifidobacterium infantis cure 21 + lactobacillus plantarum 299.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium infantis cure 21 + lactobacillus plantarum 299.